Lobe Sciences News Today

Company Exploring Alternative Value Creation Opportunities Convertible note for $500,000.00 USD, Short-term Debt Reduced and Balance Sheet Strengthened to Prepare the Company for Long Term Funding...

04.06.2024 - Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (Lobe or the Company), a biopharmaceutical company focused on developing transformative medicines to treat diseases with unmet medical needs and rare diseases announced the evaluation of strategic ... Seite 1

Providing a Proven Track Record of Driving Growth and Innovation ...

Lobe Sciences (TSE:LOBE) has released an update. Lobe Sciences Ltd., a biopharmaceutical company, has announced a change of control after Clearway ...

Lobe Sciences Ltd. , a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC , a wholly owned subsidiary of Sancilio & Company , a...

12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M for Altemia® ...

Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 ...

Lobe Sciences Ltd. ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company's lead clinical program, L-130, a proprietary stabilized...

Disclaimer IMPORTANT NOTICE. This presentation is an overview of Lobe Sciences Ltd. and is for information purposes only and should not be...

VANCOUVER, British Columbia — Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”), a North American Biopharmaceutical Company committed to…